Browse by author
Lookup NU author(s): Dr Gordon Strathdee
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Epigenetic inactivation of genes that are crucial for the control of normal cell growth is a hallmark of cancer cells. These epigenetic mechanisms include crosstalk between DNA methylation, histone modification and other components of chromatin higher-order structure, and lead to the regulation of gene transcription. Re-expression of genes epigenetically inactivated can result in the suppression of tumour growth or sensitization to other anticancer therapies. Small molecules that reverse epigenetic inactivation are now undergoing clinical trials in cancer patients. This, together with epigenomic analysis of chromatin alterations such as DNA methylation and histone acetylation, opens up the potential both to define epigenetic patterns of gene inactivation in tumours and to use drugs that target epigenetic silencing.
Author(s): Strathdee G; Brown R
Publication type: Review
Publication status: Published
Journal: Trends in Molecular Medicine
Year: 2002
Volume: 8
Issue: 4 Suppl
Pages: S43-48
ISSN (print): 1471-4914
ISSN (electronic): 1471-499X
URL: http://dx.doi.org/10.1016/S1471-4914(02)02314-6
DOI: 10.1016/S1471-4914(02)02314-6
Notes: Journal Article Review England
